摘要
目的探讨不同剂量生长抑素对肝硬化伴食管胃底静脉曲张患者胃泌素(GAS)、血红蛋白(HGB)及胰高血糖素(GLC)的影响。方法收集2018年12月至2019年12月在本院治疗的106例肝硬化伴食管胃底静脉曲张患者的临床资料,根据药物使用剂量不同分为A组(53例,标准剂量生长抑素联合普萘洛尔治疗)和B组(53例,加倍剂量生长抑素联合普萘洛尔治疗)。对比两组患者治疗后临床疗效、治疗前后GAS、HGB、GLC水平、住院指标及血流动力学指标水平,观察2组患者治疗后不良反应发生情况。结果B组总有效率(90.57%)高于A组(71.70%),差异有统计学意义(P<0.05)。与治疗前比较,两组GAS、GLC明显下降,HGB明显升高,差异有统计意义(P<0.05);治疗后B组患者GAS、GLC低于A组,HGB高于A组,差异有统计学意义(P<0.05)。A组住院时间、止血时间均长于B组,输血量高于B组,差异有统计学意义(P<0.05)。与治疗前比较,两组患者CVP、PVP均明显下降,差异具有统计学意义(P<0.05);治疗后B组患者CVP、PVP明显低于A组,差异有统计学意义(P<0.05);两组治疗前后VPV水平相近,差异无统计学意义(P>0.05)。A组患者治疗后不良反应总发生率为5.66%明显低于B组16.98%,差异有统计学意义(P<0.05)。结论加倍剂量生长抑素联合普萘洛尔治疗临床疗效好,可有效改善患者GAS、HGB、GLC水平及血流动力学指标,并缩短患者住院时间、止血时间,安全性高,临床应用价值大。
Objective To explore the effect of different doses of somatostatin on gastrin(GAS),haemoglobin(HGB)and glucagon(GLC)in patients with liver cirrhosis combined with esophageal and gastric varices.Methods The clinical data of 106 patients with liver cirrhosis combined with esophageal and gastric varices who were treated in our hospital from December 2018 to December 2019 were collected.According to the different dosages of drugs,they were divided into group A(53 cases,standard dose of somatostatin combined with propranolol)and group B(53 cases,double dose of somatostatin combined with propranolol).The clinical efficacy,levels of GAS,HGB,GLC,hospitalization indicators(hospitalization time,bleeding time,blood transfusion)and hemodynamic indicator levels before and after treatment were compared between the two groups.The incidence of adverse reactions after treatment was observed between the 2 groups.Results The total effective rate of group B(90.57%)was higher than that of group A(71.70%).The difference between the two groups was statistically significant(P<0.05).Compared with those before treatment,the levels of GAS and GLC of patients in the two groups significantly decreased,and the level of HGB significantly increased and the difference was statistically significant(P<0.05).After treatment,the levels of GAS and GLC in group B were significantly lower than those in group A,and the level of HGB was significantly higher than that in group A,the difference was statistically significant(P<0.05).The hospitalization time and bleeding time in group A were longer than those in group B,and the blood transfusion volume was higher than that in group B,the difference was statistically significant(P<0.05).Compared with those before treatment,the CVP and PVP of the two groups significantly decreased,the difference was statistically significant(P<0.05).After treatment,the levels of CVP and PVP in group B were significantly lower than those in group A(P<0.05).The levels of VPV before and after treatment in the two groups were similar,and the difference was not statistically significant(P>0.05).The total incidence of adverse reactions in group A patients after treatment was 5.66%,which was significantly lower than 16.98%in group B(P<0.05).Conclusion Doubled-dose somatostatin combined with propranolol has a good clinical effect,can effectively improve the patients'GAS,HGB,GLC levels and hemodynamic indicators,and shorten the patient's hospital stay,bleeding time.It has high safety,and great clinical application value.
作者
杨岳
李宝纯
霍建凤
YANG Yue;LI Baochun;HUO Jianfeng(Department of Gastroenterology,Qinhuangdao Second Hospital,Qinhuangdao,Hebei,China,066600;Department of Respiratory Medicine,Qinhuangdao Second Hospital,Qinhuangdao,Hebei,China,066600)
出处
《分子诊断与治疗杂志》
2021年第1期132-135,共4页
Journal of Molecular Diagnostics and Therapy
基金
秦皇岛市科学技术研究与发展计划(201805A075)。
